argenx SE trades on Nasdaq under the ticker ARGX and is one of the biotechnology sector's most closely followed immunology franchises. Over the trailing 30 days, the stock climbed approximately 5.7%, moving from around $875.76 to a recent close near $925.70. That advance reflects renewed investor confidence following positive clinical data and a strategic acquisition, though shares remain below the late-summer peak above $1,030 reached in August.
The broader setup combines a commercially proven blockbuster product with a maturing pipeline, giving the stock a profile more like a growth-stage biopharma than a speculative one. Sentiment remains constructive, supported by sustained revenue growth, expanding profit margins, and a steady cadence of late-stage catalysts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
argenx is an Amsterdam-headquartered global immunology company focused on transforming breakthroughs in antibody science into treatments for severe autoimmune diseases. Its flagship medicine, VYVGART (efgartigimod alfa), is the first approved neonatal Fc receptor (FcRn) blocker, designed to reduce circulating IgG autoantibodies. The intravenous formulation and the subcutaneous VYVGART Hytrulo are approved for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) globally, with an additional approval for primary immune thrombocytopenia in Japan.
The company's commercial engine is underpinned by a growing prescriber base and a shift toward earlier lines of treatment. Its "Vision 2030" framework targets 50,000 treated patients, 10 labeled indications, and five candidates in Phase 3 by the end of the decade. Beyond efgartigimod, the pipeline includes empasiprubart (a first-in-class anti-C2 antibody), adimanebart, and a wave of earlier-stage molecules sourced through its Immunology Innovation Program, positioning argenx as a leader in FcRn biology and precision immunology.
Several verified catalysts shaped ARGX in recent weeks. On the clinical front, argenx presented positive Phase 3 ALKIVIA data at ACR Convergence 2026, demonstrating rapid and sustained improvement with efgartigimod in autoimmune myositis, including immune-mediated necrotizing myopathy and dermatomyositis. The results support argenx's effort to bring VYVGART into rheumatology for the first time.
The company also announced a definitive agreement to acquire Unnatural Products for up to approximately $1.15 billion, including $550 million upfront. The deal adds a macrocyclic peptide discovery engine that argenx intends to leverage for oral and long-acting medicines, complementing its antibody engineering capabilities.
Fundamentals reinforce the narrative. Third-quarter 2026 product net sales were $1.7 billion, a 54% year-over-year increase, with $1.5 billion generated in the United States. The company has delivered consecutive quarters of growth and reported its first full-year profit on record 2025 sales of approximately $4.2 billion. Analyst coverage remains broadly positive, with recent price targets clustered around the low-to-mid $1,100s.
Looking ahead, several factors are likely to influence ARGX. Topline results from the EMPASSION study of empasiprubart in multifocal motor neuropathy are expected in the fourth quarter of 2026, offering a potential second pipeline readout beyond efgartigimod. Investors are also watching label-expansion efforts, including the planned VYVGART Hytrulo autoinjector launch targeted for 2027 and additional regulatory submissions across new indications.
On the commercial side, continued U.S. growth in gMG and CIDP, gross-to-net dynamics, and international expansion remain key drivers. Macroeconomic conditions, competitive dynamics in the FcRn and broader immunology space, and execution on the Unnatural Products integration will also matter. While the company's fundamentals are strong, biopharma stocks remain sensitive to clinical-trial outcomes, regulatory decisions, and shifts in sector sentiment. From what I see, monitoring these elements closely helps frame the risk-reward profile.
In my analysis of names like ARGX, I often rely on Tickeron’s AI Trading Bots to review algorithmic strategies that align with current market conditions. These tools provide a practical way to observe how data-driven approaches are interpreting developments across equities, helping me cross-check my own views without replacing fundamental research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ARGX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 39 similar instances where the stock broke above the upper band. In 26 of the 39 cases the stock fell afterwards. This puts the odds of success at 67%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 66 cases where ARGX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 58%.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARGX as a result. In 50 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ARGX's RSI Indicator exited the oversold zone, 16 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for ARGX just turned positive on October 21, 2026. Looking at past instances where ARGX's MACD turned positive, the stock continued to rise in 35 of 49 cases over the following month. The odds of a continued upward trend are 71%.
ARGX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ARGX crossed bullishly above the 50-day moving average on November 12, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
Following a +1.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARGX advanced for three days, in 215 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
The Aroon Indicator entered an Uptrend today. In 180 of 256 cases where ARGX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
The Tickeron Profit vs. Risk Rating rating for this company is 11 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ARGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 67 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.892) is normal, around the industry mean (3.596). P/E Ratio (33.413) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (1.189) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (12.330) is also within normal values, averaging (443.347).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of antibody-based medicines
Industry Biotechnology